FR2576792B1 - Composition pharmaceutique a base d'erythropoietine humaine pour le traitement de l'anemie de l'arthrite rhumatoide - Google Patents

Composition pharmaceutique a base d'erythropoietine humaine pour le traitement de l'anemie de l'arthrite rhumatoide

Info

Publication number
FR2576792B1
FR2576792B1 FR868601641A FR8601641A FR2576792B1 FR 2576792 B1 FR2576792 B1 FR 2576792B1 FR 868601641 A FR868601641 A FR 868601641A FR 8601641 A FR8601641 A FR 8601641A FR 2576792 B1 FR2576792 B1 FR 2576792B1
Authority
FR
France
Prior art keywords
anemia
treatment
pharmaceutical composition
composition based
human erythropoietin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR868601641A
Other languages
English (en)
Other versions
FR2576792A1 (fr
Inventor
Cynshi Osamu
Mizuno Koji
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of FR2576792A1 publication Critical patent/FR2576792A1/fr
Application granted granted Critical
Publication of FR2576792B1 publication Critical patent/FR2576792B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FR868601641A 1985-02-06 1986-02-06 Composition pharmaceutique a base d'erythropoietine humaine pour le traitement de l'anemie de l'arthrite rhumatoide Expired - Lifetime FR2576792B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2116585 1985-02-06

Publications (2)

Publication Number Publication Date
FR2576792A1 FR2576792A1 (fr) 1986-08-08
FR2576792B1 true FR2576792B1 (fr) 1990-03-23

Family

ID=12047297

Family Applications (1)

Application Number Title Priority Date Filing Date
FR868601641A Expired - Lifetime FR2576792B1 (fr) 1985-02-06 1986-02-06 Composition pharmaceutique a base d'erythropoietine humaine pour le traitement de l'anemie de l'arthrite rhumatoide

Country Status (4)

Country Link
US (1) US4732889A (fr)
JP (1) JPH0672103B2 (fr)
FR (1) FR2576792B1 (fr)
GB (1) GB2171304B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL77081A (en) * 1984-12-04 1999-10-28 Genetics Inst Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
GB2177914B (en) * 1985-06-04 1989-10-25 Chugai Pharmaceutical Co Ltd A pharmaceutical composition containing human erythropoietin and a surface active agent for nasal administration for the treatment of anemia
US4954437A (en) * 1986-09-15 1990-09-04 Integrated Genetics, Inc. Cell encoding recombinant human erythropoietin
JP2858752B2 (ja) * 1987-04-10 1999-02-17 オーソ・フアーマシユーチカル・コーポレーシヨン 正常な哺乳動物のヘマトクリツト値の増大方法
US4987121A (en) * 1988-05-27 1991-01-22 Center For Innovative Technology Erythropoietic factor
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5912015A (en) * 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5674534A (en) * 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US20030035845A1 (en) * 1992-06-11 2003-02-20 Zale Stephen E. Composition for sustained release of non-aggregated erythropoietin
US5614184A (en) * 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US6153407A (en) * 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
US5548064A (en) * 1993-05-24 1996-08-20 Biotech Australia Pty Limited Vitamin B12 conjugates with EPO, analogues thereof and pharmaceutical compositions
ES2206521T3 (es) 1994-11-03 2004-05-16 Roche Diagnostics Gmbh Utilizacion de la eritropoyetina en el tratamiento de artritis reumatoide.
AU710347B2 (en) * 1995-08-31 1999-09-16 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
DE19539574A1 (de) * 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
US5906978A (en) 1996-08-14 1999-05-25 Hemocleanse, Inc. Method for iron delivery to a patient by transfer from dialysate
US5952226A (en) * 1996-11-05 1999-09-14 Modex Therapeutiques Hypoxia responsive EPO producing cells
DE19734293A1 (de) * 1997-08-08 1999-02-11 Boehringer Mannheim Gmbh Verwendung von pharmazeutischen Kombinationspräparaten enthaltend Erythropoietin und Eisenpräparate zur Behandlung von rheumatischen Erkrankungen
US6696411B1 (en) * 1998-04-22 2004-02-24 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
WO1999054486A1 (fr) * 1998-04-22 1999-10-28 Cornell Research Foundation, Inc. Gene de l'erithropoietine canine et proteine recombinee
AU5649299A (en) * 1998-09-11 2000-04-03 Chugai Seiyaku Kabushiki Kaisha Protein solution preparation and method for stabilizing the same
JP2003523940A (ja) 1999-05-11 2003-08-12 オーソ−マクネイル ファーマシューティカル インコーポレイテッド エリスロポエチン投与の薬物速度論的および薬力学的モデリング
EP1232753B1 (fr) 1999-09-08 2008-03-19 Chugai Seiyaku Kabushiki Kaisha Solution de protéine stable contenue dans des récipients à base de résine hydrophobe et procédé de stabilisation associé
JP3967594B2 (ja) * 2000-05-15 2007-08-29 エフ．ホフマン−ラ ロシュ アーゲー 新しい薬剤組成物
AU2005225151B2 (en) * 2000-05-15 2008-05-29 F. Hoffmann-La Roche Ag New pharmaceutical composition
EP1295604B1 (fr) 2000-06-30 2009-09-30 Tokyo Metropolitan Institute of Gerontology Preventifs et remedes contre des maladies associees a la demyelinisation
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
US20040198663A1 (en) * 2003-04-04 2004-10-07 Baker John E. Method of treating cardiac ischemia by using erythropoietin
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
AT500929B1 (de) * 2004-11-09 2007-03-15 Medizinische Uni Wien Muw Pharmazeutische zubereitung die erythropoietin enthält
WO2008024858A2 (fr) * 2006-08-22 2008-02-28 University Of Virginia Patent Foundation Procédés et composés régulant la réponse érythroïde à une déficience en fer
JP6748375B2 (ja) 2016-10-19 2020-09-02 Ｊｆｅスチール株式会社 Ｓｉ含有熱延鋼板の脱スケール方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254095A (en) * 1978-04-27 1981-03-03 Research Corporation Radioimmunoassay for erythropoietin
JPS5653696A (en) * 1979-10-09 1981-05-13 Ajinomoto Co Inc Isolation of erythropoietin by adsorption
JPS6045849B2 (ja) * 1980-08-25 1985-10-12 林原 健 ヒトエリトロポエチンの製造方法
JPS57149228A (en) * 1981-03-11 1982-09-14 Ajinomoto Co Inc Novel erythropoietin and its preparation
JPH0686480B2 (ja) * 1983-02-21 1994-11-02 雪印乳業株式会社 エリスロポエチン製造用モノクローナル抗体
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
EP1486052B1 (fr) * 2002-03-21 2006-08-23 Nokia Corporation Dispositif electronique mobile comportant un affichage pivotant

Also Published As

Publication number Publication date
US4732889A (en) 1988-03-22
JPH0672103B2 (ja) 1994-09-14
FR2576792A1 (fr) 1986-08-08
JPS6232A (ja) 1987-01-06
GB2171304A (en) 1986-08-28
GB8602788D0 (en) 1986-03-12
GB2171304B (en) 1989-06-14

Similar Documents

Publication Publication Date Title
FR2576791B1 (fr) Composition pharmaceutique a base d'erythropoietine humaine pour le traitement de l'anemie de tumeurs malignes
GB2171304B (en) Pharmaceutical composition for the treatment of the anemia of rheumatoid arthritis
FR2508318B1 (fr) Bandage pour l'administration d'une substance pharmaceutique
FR2586562B1 (fr) Composition pharmaceutique contenant de l'a-methylhistamine
FR2584932B1 (fr) Appareil d'electrotherapie pour ionophorese
FR2582513B1 (fr) Compositions pharmaceutiques contenant de l'alfuzosine
FR2633182B1 (fr) Composition pharmaceutique anticancereuse et methode d'utilisation de l'invention
FR2488803B1 (fr) Procede pour la production d'erythropoietine humaine
IT8567478A0 (it) Composizione farmaceutica a base di difosfonati per il trattamento dell artrosi
FR2587216B1 (fr) Composition pharmaceutique a base d'erythropoietine humaine destinee a etre administree par voie nasale pour le traitement de l'anemie
FR2499408B1 (fr) Composition pharmaceutique pour le traitement de l'osteopathie, a base d'acide 6-amino-1-hydroxyhexane-1,1-diphosphonique
FR2491778B1 (fr) Procede pour la preparation de catalyseurs a base d'oxydes de molybdene et/ou de tungstene et d'oxydes d'autres metaux
FR2628973B1 (fr) Composition cosmetique ou pharmaceutique a usage cutane, et procede pour la preparation d'une telle composition
FR2488135B1 (fr) Composition pharmaceutique a base de propylene-glycol et d'acetaminophene
FR2577559B1 (fr) Procede pour l'homopolymerisation anionique d'alpha-trifluoromethylacrylate
PT66850A (fr) Procede pour la preparation d'une composition pharmaceutique
FR2558372B1 (fr) Composition medicamenteuse pour le traitement de l'acne
FR2598617B1 (fr) Composition pharmaceutique
FR2277591A1 (fr) Composition pharmaceutique pour la prevention et le traitement de l'alcoolisme
FR2574295B1 (fr) Medicaments a base de gluconate de zinc utiles pour le traitement des hyperprolactinemies
BE894228A (fr) Composition pharmaceutique pour le traitement de l'atherosclerose
FR2585953B1 (fr) Composition pharmaceutique pour l'administration orale contenant de l'ubiquinone et procede
BE819891A (fr) Composition pharmaceutique pour le traitement de l'arthrite contenant un derive d'acide fusidique
FR2586351B1 (fr) Composition pharmaceutique a base de peroxodiphosphate pour l'inactivation d'endotoxines bacteriennes
FR2581311B1 (fr) Compositions pharmaceutiques pour le traitement de colites et colopathies, a base d'essence de thym et d'huile essentielle de cade

Legal Events

Date Code Title Description
ST Notification of lapse